Refine
Has Fulltext
- yes (72)
Is part of the Bibliography
- yes (72)
Year of publication
Document Type
- Journal article (65)
- Preprint (4)
- Conference Proceeding (3)
Language
- English (72)
Keywords
- PET (17)
- prostate cancer (13)
- theranostics (13)
- positron emission tomography (11)
- CXCR4 (10)
- PET/CT (10)
- Positronen-Emissions-Tomografie (10)
- PSMA (9)
- multiple myeloma (8)
- neuroendocrine tumor (8)
- radioligand therapy (8)
- PRRT (7)
- molecular imaging (7)
- RADS (4)
- SPECT (4)
- SSTR (4)
- somatostatin receptor (4)
- 18F-DCFPyL (3)
- DaTscan (3)
- FDG (3)
- NET (3)
- PSMA-RADS (3)
- Prostate Cancer (3)
- adrenocortical carcinoma (3)
- chemokine receptor (3)
- endoradiotherapy (3)
- medicine (3)
- peptide receptor radionuclide therapy (3)
- prostate-specific membrane antigen (3)
- 18F-FDG (2)
- 18F-FDG PET/CT (2)
- C-X-C motif chemokine receptor 4 (2)
- Ioflupane (2)
- MAG3 (2)
- PSMA I&T (2)
- PSMA-PET (2)
- Parkinson (2)
- Parkinson Disease (2)
- Parkinson-Krankheit (2)
- Parkinson’s disease (2)
- Positron Emission Tomography (2)
- SSTR-RADS (2)
- SUV (2)
- TKI (2)
- Virchow Node (2)
- [177Lu]-DOTATATE/-DOTATOC (2)
- [68Ga] (2)
- [68Ga]PentixaFor (2)
- bone disease (2)
- fibroblast activation protein (2)
- lymphoma (2)
- personalized medicine (2)
- prostate-specific membrane antigen (PSMA) (2)
- radionuclide therapy (2)
- reporting and data system (2)
- salvage radiotherapy (2)
- tumor heterogeneity (2)
- vandetanib (2)
- 11C-Methionine PET/CT (1)
- 123I-Ioflupane (1)
- 177Lu (1)
- 18-F-fluorothymidine uptake (1)
- 18F-DCFPL (1)
- 2-deoxy-2-(18F)fluoro-D-glucose (1)
- 68Ga-DOTANOC (1)
- 68Ga-DOTATATE (1)
- 68Ga-DOTATOC (1)
- 68Ga-Pentixafor PET/CT (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- Arginine (1)
- COVID-19 (1)
- CTCAE (1)
- CXCR4-targeting (1)
- CXCR4/SDF-1 (1)
- CYP11B enzymes (1)
- DLBCL (1)
- DNA repair (1)
- DOTA-EB-TATE (1)
- DOTATOC (1)
- DSB damage (1)
- FDG PET/CT (1)
- FDG-PET (1)
- FLT-PET (1)
- GCA (1)
- GPR54 (1)
- Ganglia (1)
- HMDP hydroxymethylene diphosphonate (1)
- Hyperkalaemia (1)
- IBA-1 (1)
- IMAZA (1)
- Imaging pitfalls (1)
- KISS1 receptor (1)
- KISS1-54 (1)
- Lysine (1)
- MI-RADS (1)
- MRI (1)
- Merkel cell carcinoma (1)
- Molecular imaging (1)
- Myocardial-perfusion SPECT (1)
- NEC (1)
- NVP-BGT226 (1)
- PMR (1)
- PROMISE (1)
- PSA (1)
- PSA response (1)
- PSMA PET/CT (1)
- PSMA-617 (1)
- PSMA-TV (1)
- PSMA‐617 (1)
- Pancreas (1)
- Parkinsonism (1)
- Pentixafor (1)
- Pitfall (1)
- Positron emission tomography (1)
- Prostata (1)
- RLT (1)
- Radiofluorine (1)
- Radiotracer (1)
- SARS-CoV-2 (1)
- SPECT/CT (1)
- SSTR-PET (1)
- Single-Photon-Emissions-Computertomographie (1)
- Somatostatin receptor expression (1)
- TBI (1)
- TSPO (1)
- Tracer (1)
- [177Lu]/[90Y]PentixaTher (1)
- [177Lu]Lu-PSMA I&T (1)
- [177Lu]PentixaTher (1)
- [18F]FDG PET/CT (1)
- [18F]Fluorodeoxythymidine (1)
- [68Ga]DOTATOC (1)
- [68Ga]Pentixafor (1)
- [90Y]PentixaTher (1)
- [\(^{68}\)Ga] pentixafor (1)
- [\(^{68}\)Ga]Ga-FAPI (1)
- [\(^{68}\)Ga]Pentixafor (1)
- [\(^{68}\)]KISS1-54 (1)
- \(^{11}\)C-Methionine-PET (1)
- \(^{11}\)C-methionine (1)
- \(^{177}\)Lu (1)
- \(^{18}\)F (1)
- \(^{18}\)F-FDG PET/CT (1)
- \(^{18}\)F-PSMA-1007 (1)
- \(^{68}\)Ga (1)
- \(^{68}\)Ga-Pentixafor (1)
- adrenal incidentaloma (1)
- ageing (1)
- agreement (1)
- amino acids (1)
- attention deficit/hyperactivity disorder (ADHD) (1)
- autologous transplantation (1)
- autoradiography (1)
- biokinetics (1)
- biomarker (1)
- bone-marrow (1)
- cancer (1)
- cancer treatment (1)
- caudate nucleus (1)
- cells (1)
- chemokine receptor-4 (1)
- cholinergic activity (1)
- combination (1)
- comparability (1)
- diffuse (1)
- dopamine transporter (DAT) (1)
- early response (1)
- ejection fraction (1)
- esophagogastric junction (1)
- evans blue (1)
- experience (1)
- flare phenomenon (1)
- focal (1)
- follicular lymphoma (1)
- giant cell arteritis (1)
- glioblastoma (1)
- glioblastoma multiforme (1)
- glioma (1)
- head and neck cancer (1)
- health care (1)
- hematotoxicity (1)
- human tumor cell lines (1)
- hyperkalemia (1)
- imaging (1)
- imaging proliferation (1)
- imaging techniques (1)
- immunohistochemistry (1)
- immunostaining (1)
- in vivo imaging (1)
- in-vivo (1)
- inflammation (1)
- inhibition (1)
- interobserver (1)
- interreader (1)
- intraindividual comparison (1)
- involvement (1)
- irradiation (1)
- isotopes (1)
- kidney function (1)
- kisspeptin (1)
- late response (1)
- left-ventricular function (1)
- levodopa-induced dyskinesia (1)
- macrophages (1)
- macroscopic recurrence (1)
- magnetic resonance imaging (1)
- malignancies (1)
- mammalian target of rapamycin (1)
- management (1)
- matched pair (1)
- medullary thyroid carcinoma (1)
- metabolic tumor volume (MTV) (1)
- metabolic tumour volume (MTV) (1)
- methionine (1)
- methylphenidate (1)
- microenvironment (1)
- microglial cells (1)
- mouse (1)
- nephrotoxicity (1)
- neuroendocrine neoplasia (1)
- neuroinflammation (1)
- non-Hodgkin's lymphoma (1)
- non-hodgkins-lymphoma (1)
- ollimator (1)
- overall survival (1)
- pancreas (1)
- papillary thyroid carcinoma (PTC) (1)
- pattern (1)
- peptide receptor (1)
- phosphatidylinositol-3-kinase (1)
- photons (1)
- pleural mesothelioma (1)
- polymyalgia rheumatica (1)
- positron emission tomography/computed tomography (1)
- post-reconstruction filtering (1)
- prediction (1)
- progression (1)
- quality (1)
- quantification (1)
- radiogenomics (1)
- radioiodine (1)
- recurrence (1)
- relapse (1)
- renal scintigraphy (1)
- repair (1)
- reporting and data systems (1)
- responsivity (1)
- sarcoidosis (1)
- scanner (1)
- selpercatinib (1)
- signal to noise ratio (1)
- signaling pathway (1)
- simultaneous integrated boost (1)
- single photon emission computed tomography (SPECT) (1)
- skeletal (1)
- small animal SPECT (1)
- small-animal imaging (1)
- smoldering myeloma (1)
- software (1)
- solid tumors (1)
- somatostatin (1)
- somatostatin receptor (SSTR) (1)
- somatostatin receptors (1)
- staging (1)
- standardization (1)
- standardized reporting (1)
- standardized reporting system (1)
- stem-cell transplantation (1)
- striatum (1)
- super ultraviolet (1)
- survival (1)
- target (1)
- taxane (1)
- thyroid carcinoma (TC) (1)
- thyroid carcinomas (1)
- total lesion PSMA (1)
- total lesion glycolysis (TLG) (1)
- total lesion methionine uptake (TLMU) (1)
- treatment response (1)
- tumor (1)
- tyrosine kinase inhibitor (1)
- vasculature (1)
- vasculitis (1)
- vestibular schwannoma (1)
- weight drop (1)
- α-Particle (1)
- γ-H2AX (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (72) (remove)
Sonstige beteiligte Institutionen
Prostate-specific membrane antigen (PSMA)-targeted PET imaging for prostate cancer with \(^{68}\)Ga-labeled compounds has rapidly become adopted as part of routine clinical care in many parts of the world. However, recent years have witnessed the start of a shift from \(^{68}\)Ga- to \(^{18}\)F-labeled PSMA-targeted compounds. The latter imaging agents have several key advantages, which may lay the groundwork for an even more widespread adoption into the clinic. First, facilitated delivery from distant suppliers expands the availability of PET radiopharmaceuticals in smaller hospitals operating a PET center but lacking the patient volume to justify an onsite \(^{68}\)Ge/\(^{68}\)Ga generator. Thus, such an approach meets the increasing demand for PSMA-targeted PET imaging in areas with lower population density and may even lead to cost-savings compared to in-house production. Moreover, \(^{18}\)F-labeled radiotracers have a higher positron yield and lower positron energy, which in turn decreases image noise, improves contrast resolution, and maximizes the likelihood of detecting subtle lesions. In addition, the longer half-life of 110 min allows for improved delayed imaging protocols and flexibility in study design, which may further increase diagnostic accuracy. Moreover, such compounds can be distributed to sites which are not allowed to produce radiotracers on-site due to regulatory issues or to centers without access to a cyclotron. In light of these advantageous characteristics, \(^{18}\)F-labeled PSMA-targeted PET radiotracers may play an important role in both optimizing this transformative imaging modality and making it widely available. We have aimed to provide a concise overview of emerging \(^{18}\)F-labeled PSMA-targeted radiotracers undergoing active clinical development. Given the wide array of available radiotracers, comparative studies are needed to firmly establish the role of the available \(^{18}\)F-labeled compounds in the field of molecular PCa imaging, preferably in different clinical scenarios.